Lexeo Therapeutics (LXEO) Cash from Investing Activities (2022 - 2026)

Lexeo Therapeutics has disclosed Cash from Investing Activities across 5 years of filings, most recently posting $27.5 million for Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at $27.5 million, up 76.03% year-over-year; the trailing twelve-month figure through Mar 2026 was -$78.4 million (changed 0.14% YoY), and the FY2025 annual result was -$90.3 million, up 4.07% from the prior year.
• Cash from Investing Activities came in at $27.5 million for Q1 2026 at Lexeo Therapeutics, up from -$101.7 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $35.0 million in Q3 2025 to a low of -$101.7 million in Q4 2025.
• The 5-year median for Cash from Investing Activities is -$95000.0 (2022), against an average of -$13.1 million.
• Across the five-year window, Cash from Investing Activities slumped 128095.89% in 2024 and soared 42281.93% in 2025, its largest moves.
• Lexeo Therapeutics' Cash from Investing Activities stood at -$107000.0 in 2022, then jumped by 31.78% to -$73000.0 in 2023, then plunged by 128095.89% to -$93.6 million in 2024, then declined by 8.66% to -$101.7 million in 2025, then soared by 127.0% to $27.5 million in 2026.
• The last three Cash from Investing Activities figures came in at $27.5 million (Q1 2026), -$101.7 million (Q4 2025), and $35.0 million (Q3 2025), per Business Quant data.